Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen & Simcere Plot Long Run On Biosimilars In China

Oct 20 2017

• By Ying Huang

Simcere_Amgen_Partnership_China — Jinsheng Ren and Tony Hooper • Source: Simcere Pharmaceutical

Related Content

Simcere Set For Hong Kong Relisting After New Venture Success

Jan 14 2016

Hangzhou’s Attractions Play Big Part In New Pfizer China Investment

Jun 30 2016

Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China

Dec 16 2016

New $350m Site To Build Pfizer’s China Biosimilar Capacity

Jun 28 2016

Related Companies

Amgen, Inc.

Simcere Pharmaceutical Group

AbbVie Inc.

Genentech, Inc.

Bristol Myers Squibb Company

Orphan Disease Treatment Institute Co., Ltd.

GSK plc

Apexigen, Inc.

Innovent Biologics, Inc.

Livzon Pharmaceutical Group Inc.

Pfizer Inc.

Sanofi

Eden Biologics, Inc.

Additional Topics

China Asia Pacific Biosimilars Business Strategies Commercial Strategy BioPharmaceutical

More from China

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window